Lupin gets tentative US FDA approval for Trandolapril

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, 19 December 2006: Lupin Ltd., announced today that the US FDA has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Trandolapril Tablets, 1mg, 2mg and 4mg. Trandolapril is indicated for the treatment of hypertension.

Lupin's Trandolapril Tablets will be the AB-rated generic equivalent of Abbott's Mavik® Tablets. Annual product sales in the U.S. of the tablets were approximately $53 million for the twelve months ended July 2006, based on IMS data.

The Company intends to launch the generic on final approval which is expected upon expiry of patent protection for the brand product in June 2007.

About Lupin
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the half-year ended September 2006, the Company's Revenues and Profit after Tax were Rs.9,917 million (US$ 220 million) and Rs.1,090 million (US$ 24 million) respectively.

For further information contact:
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com